Rutgers Cancer Institute

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

Funding cuts to childhood cancer research have put the subspecialty in a precarious position during Childhood Cancer Awareness Month.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.

Pharmacists are being asked to not only manage medications and side effects but also be fiscally responsible for the whole institution and its trickle-down effect on costs, said David Awad, PharmD, BCOP, of Robert Wood Johnson University Hospital.

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute, introduces New Jersey's new state-of-the-art facilities at the Jack & Sheryl Morris Cancer Center.

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.

Effective toxicity management in oncology requires pharmacists to document interventions clearly and collaborate closely with multidisciplinary teams, says David Awad, PharmD, BCOP.

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

David Awad, PharmD, BCOP, says pharmacists play a growing role in managing access, safety, and toxicity for these therapies, ensuring treatments are appropriate and sustainable in real-world oncology practice.

Multidisciplinary efforts help promote the success of clinical trials and innovation for patients with various forms of lymphoma, explained Andrew Evens, DO.

To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.

Clinical approaches to non-Hodgkin lymphoma in younger and older patient groups generally do not differ, according to Andrew Evens, DO, but he emphasized the need for deeper clinical insights into potential biologic differences in younger oncology patients.

Adolescent and Young Adult Cancer Awareness Week serves as an opportunity to shed light on the special considerations and experiences of younger oncology patient populations.

Bonnie Qin, PhD, assistant professor at Rutgers Cancer institute, discusses factors that may influence adherence to dietary guidelines and improve survival for Black women with ovarian cancer.

Bonnie Qin, PhD, of Rutgers Cancer Institute, emphasizes that moderate improvements in prediagnosis dietary quality can significantly enhance survival rates among Black women diagnosed with high-grade serous ovarian cancer.